Absher Wealth Management LLC Sells 3,464 Shares of Amgen Inc. $AMGN

Absher Wealth Management LLC lowered its position in shares of Amgen Inc. (NASDAQ:AMGN) by 4.4% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 74,920 shares of the medical research company’s stock after selling 3,464 shares during the period. Amgen comprises about 3.1% of Absher Wealth Management LLC’s investment portfolio, making the stock its 19th biggest holding. Absher Wealth Management LLC’s holdings in Amgen were worth $26,361,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. IFC Advisors LLC increased its position in shares of Amgen by 2.2% in the first quarter. IFC Advisors LLC now owns 2,751 shares of the medical research company’s stock valued at $968,000 after acquiring an additional 58 shares during the period. Global Assets Advisory LLC lifted its holdings in Amgen by 6.9% in the 1st quarter. Global Assets Advisory LLC now owns 3,676 shares of the medical research company’s stock worth $1,293,000 after buying an additional 238 shares during the period. Trifecta Capital Advisors LLC lifted its holdings in Amgen by 2.9% in the 1st quarter. Trifecta Capital Advisors LLC now owns 15,992 shares of the medical research company’s stock worth $5,627,000 after buying an additional 458 shares during the period. Valmark Advisers Inc. grew its position in shares of Amgen by 1.5% in the 1st quarter. Valmark Advisers Inc. now owns 8,726 shares of the medical research company’s stock worth $3,070,000 after buying an additional 133 shares during the last quarter. Finally, Pittenger & Anderson Inc. increased its stake in shares of Amgen by 2.0% during the first quarter. Pittenger & Anderson Inc. now owns 3,033 shares of the medical research company’s stock valued at $1,067,000 after buying an additional 60 shares during the period. Institutional investors own 76.50% of the company’s stock.

Amgen Stock Performance

Shares of AMGN stock opened at $363.39 on Monday. Amgen Inc. has a 12 month low of $269.77 and a 12 month high of $391.29. The stock has a market cap of $196.13 billion, a PE ratio of 25.29, a price-to-earnings-growth ratio of 3.59 and a beta of 0.41. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. The company’s fifty day moving average price is $344.81 and its 200-day moving average price is $349.45.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The company had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. During the same period last year, the company posted $4.90 EPS. Amgen’s revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, equities analysts expect that Amgen Inc. will post 22.32 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Royal Bank Of Canada restated a “positive” rating on shares of Amgen in a report on Thursday, June 18th. The Goldman Sachs Group set a $389.00 price objective on shares of Amgen in a report on Friday, June 5th. Argus dropped their target price on shares of Amgen from $400.00 to $375.00 and set a “buy” rating for the company in a research report on Wednesday, May 20th. Canaccord Genuity Group began coverage on shares of Amgen in a research note on Monday, April 20th. They set a “hold” rating and a $366.00 target price on the stock. Finally, Guggenheim reduced their price target on shares of Amgen from $351.00 to $340.00 and set a “neutral” rating on the stock in a research report on Monday, May 4th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $355.73.

Insider Activity at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the transaction, the senior vice president owned 7,009 shares in the company, valued at approximately $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.85% of the stock is currently owned by corporate insiders.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.